AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The U.K. health secretary stressed that the risk of developing a blood clot after receiving the AstraZeneca shot was about the same as on a long-haul flight.

Officials rush to defend AstraZeneca Covid vaccine after UK, EU blood clot guidance

Two heavyweight banks repeated their bullish calls on AstraZeneca (LON:AZN) in the wake of a double dose of bad news this week. Making major headlines has been the apparent link between Oxford-developed Covid jab AZ manufactures and rare but potentially fatal blood clots.

Are AstraZeneca shares still a 'buy'? These two heavyweight banks think so

Spain and Italy have joined other European countries in limiting the use of the AstraZeneca COVID-19 vaccine to the elderly, over concerns of possible links to very rare blood clotting.

Europe's vaccine woes continue as Spain and Italy halt use of AstraZeneca shot for under-60s

Vaccitech, the company behind the AstraZeneca PLC (LON:AZN)/Oxford University COVID-19 jab, is preparing to float in New York. The valuation could be as high as US$700mln (£509mln), The Wall Street Journal reported, with some backers expecting it to rocket to US$1bn by the end of 2021.

AstraZeneca COVID-19 jab developer Vaccitech prepares for £509mln New York IPO

The World Health Organization said Wednesday it's "plausible" that there's a tie between AstraZeneca's COVID-19 vaccine and rare reports of blood clots, but this still has not been confirmed. The WHO went on to say that additional studies are needed to understand the relationship between the vaccine and any risk factors, and that a group of clinical experts should be convened to recommend how to manage these cases when they arise.

WHO: 'Plausible' tie between AstraZeneca's COVID-19 vaccine and reports of blood clots

The benefits of the vaccine still outweigh the possible risks of side effects, says the European Medicines Agency.

AstraZeneca COVID-19 vaccine: EU regulator says blood clots should be listed as rare side effect

Europe's medicines agency also found a possible link between the vaccine and blood clotting, though repeatedly stressed the vaccine's benefits outweighed its risks.

U.K. Watchdog U-Turns On AstraZeneca: Says Under 30s Should Take Alternative Covid-19 Vaccine

The European Union drug regulator said that “unusual blood clots” should be listed as a “very rare” side effect of the AstraZeneca vaccine, but insisted the benefits of the shot outweigh the risks.

EU and U.K. regulators say AstraZeneca vaccine is safe, but Brits under 30 to be offered alternative shot

The European Medicines Agency (EMA), after an in-depth analysis, has concluded that unusual blood clots should be listed as a “very rare side effect” of the Oxford/AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine. What Happened: The EMA's safety committee said that it considered all the available evidence around the instances of unusual blood clots with low blood platelets in people who received AstraZeneca's shot.

Europe's Drug Watchdog Concludes Possible Link Between AstraZeneca COVID-19 Vaccine And Blood Clots

The UK has announced a “change of course” with the vaccination programme in relation to the AstraZeneca PLC (LON:AZN)/Oxford University COVID-19 jab. Professor Lim Wei Shen, chair of COVID-19 immunisation at the Joint Committee on Vaccination and Immunisation (JCVI), said that those who are aged 18 to 29, and don't have any underlying issues making them vulnerable to the virus, should be offered another vaccine.

AstraZeneca should not be offered to healthy under 30s, UK government says

The AstraZeneca coronavirus vaccine should not be given to people under the age of 30, UK regulators said Wednesday. The news was reported by the Guardian and MailOnline just before a briefing by UK government officials. Selected media had been briefed on the conclusion in advance.

Under-30s should not take the AstraZeneca vaccine, UK regulators say, citing rare blood clots

Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.

AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study

The organization recommends rare blood clotting be listed as a very rare side effect of the vaccine.

AstraZeneca Covid-19 Vaccine Possibly Linked To Rare Blood Clots, European Medicines Agency Says

Unusual blood clots that are potentially fatal should be listed as "very rare side effects" of AstraZeneca's COVID-19 vaccine, the European medicines regulator said Wednesday. The benefits of AstraZeneca's vaccine still outweighed the risks, the The European Medicines Agency's (EMA) said in a press release.

Unusual, potentially fatal blood clots are a 'very rare side effect' of AstraZeneca's vaccine, regulators say

The benefits of the COVID-19 vaccine developed by AstraZeneca PLC (LON:AZN)/Oxford University outweigh risks of side effects, said the European Medicines Agency (EMA). A representative of the EU regulator said “vaccination is extremely important” at a press conference on Wednesday afternoon.

AstraZeneca COVID-19 vaccine fine for use, says EU regulator

It comes after a review of all currently available evidence into extremely rare cases of unusual blood clots in some vaccinated people.

EU medicines regulator finds possible link between AstraZeneca Covid vaccine and blood clots

In an unprecedented move, several European countries are looking at COVID-19 vaccines mix up for people who have received the first dose of AstraZeneca Plc's (NASDAQ: AZN) shot, as the bloc is struggling to tame fresh rises in infections, reports Reuters After a small number of reports, vaccination programs have been upset that recipients of the AstraZeneca inoculation have suffered extremely rare blood clots.

European Countries Mull Mixing COVID-19 Shot Amid AstraZeneca Crisis: Reuters

Alexion Pharma

SSR Mining

Patient investors can make bank from these well-run businesses.

3 Value Stocks That'll Make You Richer in Q2 (and Beyond)

The U.K. reported last week that it has seen 30 severe blood clotting cases out of 15.8 million administered doses of the AstraZeneca vaccine.

Oxford Said To Pause Trial Of AstraZeneca Vaccine In Children, Teens Amid Blood Clot Concerns

There is a link between AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine and rare blood clots in the brain, but the possible causes are still unknown, Marco Cavaleri for the European Medicines Agency (EMA) said in an interview, reports Reuters. What Happened: “In my opinion, we can now say it, it is clear that there is an association (of the brain blood clots) with the vaccine.

'EMA Italy Official Opines Without Evidence That AstraZeneca COVID-19 Shot Linked To Blood Clots In Brain: Report'

The European Union has reportedly denied blocking shipments of 3.1 million doses of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine to Australia. According to Reuters, the Australian government says that the country has little hope of getting the remaining 400,000 doses it has been promised on time.

AstraZeneca COVID-19 Vaccine Export To Australia Not Stopped By Europe: Reuters

The University of Oxford has paused administering doses of the COVID-19 vaccine it developed with AstraZeneca PLC in a small U.K. study aimed at evaluating its safety and effectiveness in children and teenagers, to wait for further information on rare blood-clotting issues that have been found in a small group of adults that received it, the Wall Street Journal reported Tuesday. The trial was started in mid-February and involves more than 200 young people aged 6 to 17 years old, the paper said.

Oxford halts trial of AstraZeneca COVID vaccine in children and teenagers over blood-clotting issue

The regulator has repeatedly said the benefits of vaccination outweigh the risks, a view shared by the World Health Organization.

AstraZeneca Covid-19 Vaccine Has ‘Clear' Link To Rare Blood Clots, European Public Health Official Says

There is a link between the AstraZeneca vaccine and rare blood clots, according to a senior official at the European Medicines Agency.

AstraZeneca vaccine linked to rare blood clots, EMA official tells newspaper

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a collaboration agreement with Massachusetts General Hospital (MGH), leveraging robust data and clinical best practices to create digital health solutions that address today's most urgent healthcare challenges. Catalyzed by the COVID-19 pandemic and a shared mission to improve care for patients with chronic illness, this novel partnership is focused on creating and clinically validating patient-centric digital health solutions and

News for AstraZeneca Stock (AZN)